Protein Therapeutics Development and Analysis

Protein therapeutics encompass a diverse class of biologics—including monoclonal antibodies, antibody fragments, cytokines and engineered enzymes—designed to target specific molecular pathways in disease. The development pipeline begins with target identification and discovery of high-affinity binders, followed by engineering of stability, specificity and pharmacokinetics through techniques such as humanisation, affinity maturation and half-life extension. Analytical characterisation employs biophysical methods (for example chromatography, mass spectrometry and light scattering) to assess purity, aggregation and post-translational modifications, alongside in vitro and in vivo assays to evaluate potency, immunogenicity and safety. Recent advances in microfluidics and machine learning have accelerated screening of single B-cells and prediction of antibody “nativeness,” thereby streamlining candidate selection. Such innovations are transforming the global landscape of therapeutic proteins, enabling rapid response to emerging pathogens, personalised treatments for cancer and autoimmune disorders, and the design of next-generation bioconjugates for targeted delivery.

Research from Nature Portfolio

Emerging work has introduced a microfluidic platform that encapsulates individual antibody-secreting cells within hydrogel droplets, enabling high-throughput flow cytometric sorting of antigen-specific plasma cells. This approach has achieved rapid isolation of monoclonal antibodies with sub-picomolar affinities and potent neutralising activity in under two weeks, markedly expanding access to underexplored immune repertoires. In parallel, a deep learning framework has been developed to compute a “nativeness score” for antibody and nanobody sequences, predicting their similarity to naturally derived immune proteins. The tool generates interpretable residue-level profiles to guide humanisation and engineering, and an automated pipeline has demonstrated preservation of binding and stability in humanised nanobody candidates, outperforming conventional design strategies.

Research from all publishers

A comprehensive review of therapeutic antibody development has highlighted the explosive growth of the monoclonal antibody market, the evolution of phage display, transgenic mouse platforms and single-cell cloning technologies, and current approaches to humanisation and affinity maturation. This analysis underlined how improvements in expression systems and downstream processing have reduced adverse effects and enabled approvals across oncology, immunology and infectious disease. Additionally, a survey of recent protein-engineering trends has showcased rational design of fusion proteins, cytokine variants and enzyme prodrugs, emphasising strategies to modulate efficacy, half-life and immunogenicity. The study also discussed the integration of high-throughput screening and computational modelling to fine-tune functional properties while maintaining rigorous safety profiles.

Protein Therapeutics Development and Analysis publication trend

The graph below shows the total number of articles in protein therapeutics development and analysis across all publications each year (not limited to Nature Index journals).

Technical terms

Monoclonal antibody: A homogeneous immunoglobulin molecule derived from a single B-cell clone, engineered for high specificity to a target antigen.

Nanobody: A single-domain antibody fragment derived from camelid heavy-chain antibodies, notable for small size, high stability and tissue penetration.

Phage display: A laboratory technique in which peptide or protein libraries are presented on bacteriophage surfaces for selection of high-affinity binders.

Microfluidics: The manipulation of minute fluid volumes in microfabricated channels, enabling single-cell encapsulation and high-throughput assays.

Nativeness score: A predictive metric generated by machine learning to assess how closely an antibody sequence resembles naturally occurring immune repertoires.

References

1. Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells. Nature Biotechnology (2024).
2. Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV. Nature Machine Intelligence (2024).
3. Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science (2020).
4. Recent advances in (therapeutic protein) drug development. F1000Research (2017).